Experts Commend Amylyx for Withdrawing ALS Drug Relyvrio Following Trial Failure

1. Experts have praised Amylyx for honoring their commitment to withdraw Relyvrio, an ALS drug, after the clinical trial failed to demonstrate its efficacy.
2. The decision came less than a month after the critical Phase 3 trial did not prove that Relyvrio could slow down the progression of ALS symptoms.
3. During the initial approval process by the FDA in 2022, Amylyx had been questioned about their intentions should the Phase 3 trial fail.
4. John Maraganore expressed admiration for Amylyx, stating that they "walked the talk" with regard to their promise.
5. Max Gelman also highlighted experts' appreciation for Amylyx's actions.